Treatment of Crohn’s disease with colony-stimulating factors: An overview
Authors Guidi L, Mocci G, Marzo M, Rutella S
Published 10 October 2008 Volume 2008:4(5) Pages 927—934
Luisa Guidi1, Giammarco Mocci1, Manuela Marzo1, Sergio Rutella2
1Department of Internal Medicine, Operative Unit of Gastroenterology, and 2Department of Hematology, Laboratory of Immunology, Università Cattolica del Sacro Cuore, Rome, Italy
Abstract: Current treatments for Crohn’s disease are aimed at suppressing excessive immune activation in the bowel walls. However, alternative strategies can be drawn. These involve the augmentation of the innate immune response, in the hypothesis that patients affected with Crohn’s disease are characterized by a relative immunodeficiency, with failure of the defensive barrier to luminal microbes and microbial products, resulting in a chronic inflammatory process sustained by T-cells. Alternatively, therapy could act by enhancing the number or the activity of subpopulations of T regulatory cells, able to reduce T-cell activation. Colony-stimulating factors are substances that could be efficacious in these settings. In fact, besides in vitro and animal studies, some human studies have been conducted in recent years with both granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor, the results of which are reported here.
Keywords: inflammatory bowel disease, Crohn’s disease treatment, G-CSF, GM-CSF
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]